- Home
- MEIP vs STG Comparison
MEIP vs STG Comparison
Compare MEIP & STG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MEIP
- STG
- Stock Information
- Founded
- MEIP 2000
- STG 2003
- Country
- MEIP United States
- STG China
- Employees
- MEIP N/A
- STG N/A
- Industry
- MEIP Biotechnology: Pharmaceutical Preparations
- STG Other Consumer Services
- Sector
- MEIP Health Care
- STG Real Estate
- Exchange
- MEIP Nasdaq
- STG Nasdaq
- Market Cap
- MEIP 153.9M
- STG 132.6M
- IPO Year
- MEIP 2003
- STG 2018
- Fundamental
- Price
- MEIP $3.00
- STG $8.81
- Analyst Decision
- MEIP
- STG
- Analyst Count
- MEIP 0
- STG 0
- Target Price
- MEIP N/A
- STG N/A
- AVG Volume (30 Days)
- MEIP 790.3K
- STG 9.8K
- Earning Date
- MEIP 09-23-2025
- STG 08-14-2025
- Dividend Yield
- MEIP N/A
- STG N/A
- EPS Growth
- MEIP N/A
- STG N/A
- EPS
- MEIP N/A
- STG 3.59
- Revenue
- MEIP N/A
- STG $279,374,215.00
- Revenue This Year
- MEIP N/A
- STG N/A
- Revenue Next Year
- MEIP N/A
- STG N/A
- P/E Ratio
- MEIP N/A
- STG $2.43
- Revenue Growth
- MEIP 33.76
- STG N/A
- 52 Week Low
- MEIP $1.46
- STG $4.28
- 52 Week High
- MEIP $9.00
- STG $15.00
- Technical
- Relative Strength Index (RSI)
- MEIP 26.36
- STG 45.62
- Support Level
- MEIP $3.85
- STG $8.00
- Resistance Level
- MEIP $5.50
- STG $9.32
- Average True Range (ATR)
- MEIP 0.37
- STG 0.67
- MACD
- MEIP -0.20
- STG -0.18
- Stochastic Oscillator
- MEIP 3.10
- STG 29.67
About MEIP MEI Pharma Inc.
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.
About STG Sunlands Technology Group
Sunlands Technology Group is a provider of online post-secondary and professional education services in China. The company offers various degree- and diploma-oriented post-secondary courses through its online platforms. In addition, it provides online professional courses and educational content to help students prepare for professional certification exams and attain professional skills. The Group has one operating segment, which is the provision of online education services.